Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension

manilatimes.net · 2026-10-12

Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with FOP

TickrTrends take: Regeneron's Pasatru demonstrated clinical efficacy in preventing new bone formation in FOP patients during the trial extension, which could support the drug's commercial potential in this rare disease indication. Given that REGN is currently valued as fairly valued according to TickrTrends, investors focused on valuation should monitor whether positive trial results translate into regulatory approval timelines and peak sales estimates for this orphan drug. The Healthcare sector dynamics and competitive landscape for rare genetic disease treatments will be important factors in determining whether this development justifies any valuation adjustment from the current fair value assessment.

Read the full story at manilatimes.net →